[Lung survival or healing? Description of a case of acute non-lymphoblastic leukosis].
Only few patients (3,8%) affected by ANLL survive for more than 3 years from the time of diagnosis. In the present study the Authors try to determine which clinical and haematological factors can determine long-terme survival. The Authors describe the case of a male patient (25 years old) affected by ANLL (M2), who became and is still now a long-survivor (80 months from 1th complete remission). He has been treated with DNB, ARA-C and TG (TRA schedule) for two cycles. After CR he refused consolidation and reinduction therapy and was treated only with 6-MP and MTX for 3 years, as maintenance chemotherapy. The Authors suggest that important factors for a favourable prognosis are early diagnosis and young age. A relatively high number of platelets can be correlated with a good prognosis.
D000208:Acute Disease; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D013866:Thioguanine / Q000008:administration & dosage
D003561:Cytarabine; D013866:Thioguanine; D008727:Methotrexate; D003630:Daunorubicin
Lunga sopravvivenza o guarigione? Descrizione di un caso di leucosi acuta non linfoblastica.